|4Feb 21, 4:54 PM ET

Upnorth Investment Ltd 4

4 · TCR2 THERAPEUTICS INC. · Filed Feb 21, 2019

Insider Transaction Report

Form 4
Period: 2019-02-19
Transactions
  • Conversion

    Common Stock

    2019-02-19+1,614,5171,937,419 total(indirect: By Upnorth Investment Limited)
  • Conversion

    Series A Preferred Stock

    2019-02-192,000,0000 total(indirect: By Upnorth Investment Limited)
    Common Stock (322,902 underlying)
  • Conversion

    Series B Preferred Stock

    2019-02-1910,000,0000 total(indirect: By Upnorth Investment Limited)
    Common Stock (1,614,517 underlying)
  • Conversion

    Common Stock

    2019-02-19+322,902322,902 total(indirect: By Upnorth Investment Limited)
  • Purchase

    Common Stock

    2019-02-19$15.00/sh+200,000$3,000,0002,137,419 total(indirect: By Upnorth Investment Limited)
Footnotes (3)
  • [F1]Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.
  • [F2]The reported securities are owned directly by Upnorth Investment Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
  • [F3]Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION